Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

Article  CAS  PubMed  Google Scholar 

Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.

Article  PubMed  Google Scholar 

Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.

Article  CAS  PubMed  Google Scholar 

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SVR, Zhang K, Seven-Up Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.

Article  PubMed  Google Scholar 

Wada I, Oshima Y, Shiose S, Kano K, Nakano S, Kaizu Y, et al. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefes Arch Clin Exp Ophthalmol. 2019;257:1411–8.

Article  CAS  PubMed  Google Scholar 

Maruko I, Ogasawara M, Yamamoto A, Itagaki K, Hasegawa T, Arakawa H, et al. Two-year outcomes of treat-and extend intravitreal aflibercept for exudative age-related macular degeneration. A prospective study. Ophthalmol Retina. 2020;4:767–76.

Article  PubMed  Google Scholar 

Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal afliberecept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37:1173–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, et al. The angiopoietin/Tie pathway in retinal vascular diseases. A review. Retina. 2021;41:1–19.

Article  CAS  PubMed  Google Scholar 

Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.

Article  CAS  PubMed  Google Scholar 

Mitchell J, Brose LS, Bradley C. Design of a measure of satisfaction with treatment for macular degeneration (MacTSQ). Qual Life Res. 2007;A-120:2.

Google Scholar 

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomized controlled trial. Lancet. 2013;382:1258–67.

Article  CAS  PubMed  Google Scholar 

Morken TS, Knutsen C, Hanseen MS, Austeng D. Patient satisfaction following a switch from treat-and-extend to observe-and-plan regimen in age-related macular degeneration. BMJ Open. 2022;7: e000930. https://doi.org/10.1136/bmjophth-2021-000930.

Article  Google Scholar 

Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23:127–40.

Article  PubMed  Google Scholar 

Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchof B, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol. 2013;251:1281–4.

Article  CAS  PubMed  Google Scholar 

Holz FG, Schmitz-Valckenberg S, Wolf A, Agostini H, Lorenz K, Pielen A, et al. A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study. Graefes Arch Clin Exp Ophthalmol. 2022;260:2695–702.

CAS  PubMed  PubMed Central  Google Scholar 

Kitajima Y, Maruyama-Inoue M, Ikeda S, Ito A, Inoue T, Yanagi Y, et al. Short-term outcomes of switching to brolucizumab in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol. 2022;66:511–7.

Article  CAS  PubMed  Google Scholar 

Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sorbin L, Eliot D, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156:29–25.

Article  CAS  PubMed  Google Scholar 

Gupta OP, Shienbaum G, Patel AH, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134–40.

Article  PubMed  Google Scholar 

Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;16:4041–6.

Article  PubMed  PubMed Central  Google Scholar 

Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Prez LI, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.

Article  PubMed  Google Scholar